2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2097

Cardiolipin-Producing Candidate Commensals in the Gut Microbiome of Antiphospholipid Syndrome Patients
Abstract Number: 2098

Non-Criteria Anti-Phospholipid Antibodies in SLE Patients
Abstract Number: 2099

Micrornas As Potential Modulators of Atherothrombosis in Antiphospholipid Syndrome
Abstract Number: 2100

Pharmaceutical Disruption of B2GPI CXCL4 Complex Using Computationally Designed Oligopeptides
Abstract Number: 2101

the Association Between ABO Blood Types and Venous Thromboembolism in Individuals with a Positive Antiphospholipid Antibody Profile Is Varied By Sex
Abstract Number: 2102

the Prevalence and Associations of IgG/a/M ANTI-β2GPI and ANTI-Domain I Antibodies in an Antiphospholipid Syndrome (APS) Cohort of Patients from Turkey
Abstract Number: 2103

Peripheral Blood B Cells Are Expanded and Their Cytokine Expression Is Dysregulated in Juvenile Dermatomyositis
Abstract Number: 2104

Treatment with Tocilizumab Decreases CXCL13 Expression in Cultured Temporal Arteries from Patients with Giant Cell Arteritis
Abstract Number: 2105

Autoimmune Pancreatitis-Associated Autoantigens Among 100 IgG4-Related Diseases Patients
Abstract Number: 2106

Regulation of Marginal Zone B Cell Differentiation By microRNA-146a
Abstract Number: 2107

Targeting Mir-155 in Rheumatoid Arthritis B Cells Reduces Antibody Production
Abstract Number: 2108

DNA Hypomethylation in Promoter Region of Zbtb38 Gene Ultimately Leads to Downregulated Expression of Anti-Inflammatory IL1r2 in Experiential Model of Rheumatoid Arthritis
Abstract Number: 2109

Immunoprofiling of Bruton’s Tyrosine Kinase (Btk)/Tec Family Kinase Inhibitors Indicate Activities Beyond Btk in Immunocyte Function
Abstract Number: 2110

Synovial Fibroblasts Regulate B Cell Survival Via B Cell Activating Factor of the TNF Family (BAFF)
Abstract Number: 2111

Generation and Characterization of Anti-Citrullinated Protein Antibody-Producing B-Cell Clones

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].